Male contraceptive - Schering AG/Organon

Drug Profile

Male contraceptive - Schering AG/Organon

Alternative Names: Etonogestrel/testosterone undecanoate; Male Pill - Schering/Organon; ORG 3236 plus testosterone undecanoate; Testosterone undecanoate/etonogestrel

Latest Information Update: 13 Nov 2006

Price : $50

At a glance

  • Originator Bayer Schering Pharma; Organon
  • Class
  • Mechanism of Action Progesterone receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pregnancy

Most Recent Events

  • 13 Nov 2006 Discontinued - Phase-II for Pregnancy (Prevention)/Male contraception in Europe (Intradermal)
  • 23 Jan 2004 Schering and Organon has initiated enrolment in a phase II trial for Pregnancy (Prevention)/Male Contraception in 14 centres throughout Europe
  • 21 Nov 2002 Phase-II clinical trials in Pregnancy (Prevention)/Male contraception in Europe (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top